key: cord-1051696-9d96e2t3
authors: Amirfakhryan, Hamideh; safari, Fatemeh
title: Outbreak of SARS-CoV2: Pathogenesis of infection and cardiovascular involvement
date: 2020-06-06
journal: Hellenic J Cardiol
DOI: 10.1016/j.hjc.2020.05.007
sha: bc8fbc8363cef011b89fa8c7cb1acbd67078c7c1
doc_id: 1051696
cord_uid: 9d96e2t3

Since the new coronavirus SARS (SARS-CoV2) has emerged from china, the infection (COVID-19) has affected many countries and led to many deaths worldwide. Like SARS-CoV, ACE2 as a functional receptor for SARS-CoV2 is essential for virus to entry to the cell. ACE2 is a part of RAS which is expressed in several organs that opposes the AngII functions by converting Ang II to Ang (1-7), the one with vasodilation effects. The death rate of COVID-19 is estimated about 3.4%, however, some comorbid conditions like underlying cardiovascular disease, hypertension, and diabetes increase the risk of mortality. In addition, cardiovascular involvement by SARS-CoV2 could be direct through either ACE2 receptors which are expressed tremendously in heart, or by the surge of different cytokines or by ARDS-induced hypoxia. Traditional risk factors could aggravate the process of COVID-19 infection that urges the triage of these high risk patients for SARS-CoV2. Currently, there is no effective, proven treatment or vaccination for COVID-19, but many investigators are struggling to find a treatment strategy as soon as possible. Some potential medications like chloroquine by itself or in combination with azithromycin, and some protease inhibitors used for the treatment of COVID-19 have cardiovascular adverse effects that should be kept in mind in order to close monitor of the patients receiving these medications.

The Chinese CDC report has divided the clinical manifestations of COVID-19 by severity of symptoms. 81% of cases have mild symptoms including mild pneumonia; 14% of cases showed severe manifestations like dyspnea, respiratory frequency ≥ 30/min, blood oxygen saturation (SpO2) ≤ 93%, PaO2/FiO2 ratio [the ratio between the blood pressure of the oxygen (partial pressure of oxygen, PaO2) and the percentage of oxygen supplied (fraction of inspired oxygen, FiO2)] < 300, and/or lung infiltrates > 50% within 24 to 48 hours; and 5% of cases showed critical expressions like respiratory failure, septic shock, and/or multiple organ dysfunction (MOD) or failure (MOF) (4) .

The death rate of Covid-19 globally is estimated 3.4% according to WHO. (1) . However, the fatality rate of Covid-19 will be higher in special populations with comorbid diseases like Cancer (5.6%), Hypertension (6.0%), Chronic respiratory disease (6.3%), Diabetes (7.3%), and Cardiovascular disease (CVD) (10.5%) (3).

Previous studies have shown a relationship between cardiovascular metabolic diseases and severe acute respiratory syndrome (SARS) and Middle East Respiratory coronavirus (MERS), the two other types of corona viruses that reached epidemic a few years ago (5) (6) (7) .

In a systematic analysis of 637 MERS-CoV cases by Badawi, et al; it was reported that diabetes and hypertension are prevalent in about 50% of the patients and cardiac diseases are present in 30% of the cases (7) .

Currently, there is not any proven therapeutic medication for COVID-19, and conservative strategies including cardiorespiratory ventilation support are the main approach. Knowing the pathogenesis of COVID-19 infection could help developing effective medication.

It has been identified that angiotensin converting enzyme 2 (ACE2) is the essential receptor for SARS-CoV virus to entry to the cell (8) (9) (10) (11) . Lung and cardiovascular involvement by SARS-CoV2 are the two main causes of death among these patients. In this review, the pathophysiology of SARS-CoV2 infection along with a special focus on cardiovascular involvement have been explained.

The family Coronaviridae includes a large number of viruses that are found in birds and mammals (12, 13) . At first, human coronaviruses were characterized in the 1960s, and are linked with a large percentage of respiratory infections both in children and adults (12) . During the SARS-CoV epidemic in the late 2002, globally, more than 8000 human cases and 774 deaths occurred (12) . After the SARS epidemic, bats have been considered as a potential reservoir species that could be concerned in future coronavirus-related human pandemics (14) .

During 2012, MERS-CoV emerged in Saudi Arabia (15, 16) and 919 out of 2521(35%) deaths occurred (17) . A main role in the transmission of the virus to humans has been attributed to dromedary camels (18) , and its origin has been again suggested to bats (19) .

Full-genome sequence analysis of new coronavirus (SARS-CoV2) revealed that it belongs to betacoronavirus, but it is divergent from SARS-CoV and MERS-CoV that caused epidemics in the past (20) . The analysis of the genome of the SARS-CoV 2 by Paraskevis and his colleagues showed that although it is closely related to BatCoV RaTG13 sequence throughout the genome (sequence similarity 96.3%), there is a discordant clustering with the Bat_SARS-like coronavirus sequences showing that BatCoV RaTG13 does not provide the exact variant that caused the outbreak in humans, but the hypothesis that SARS-CoV2 has devised from bats is very prospective (21) .

Renin-angiotensin-aldosterone-system is a vital complex system in human body for survival by maintaining vascular tone, regulating extracellular fluid, and arterial pressure (22, 23) .

Prorenin, the precursor of renin, which is a 406 aminoacid-long protein could be proteolytically activated in the kidney by neuroendocrine convertase 1 (proprotein convertase 1) or cathepsin B and non-proteolytically in many tissues by renin/prorenin receptor (24) . The secreted renin hydrolyzes liver-secreted protein angiotensinogen to angiotensin (Ang) I (25) .

Ang I undertakes cleavage in the lungs capillaries, endothelial cells, and kidney epithelial cells by the endothelial-bound angiotensin-converting enzyme (ACE). ACE is a carboxypeptidase enzyme, also known as kininase II, converts angiotensin I into the peptide Ang II which has vasoconstrictive role on all blood vessels, and degrades bradykinin as well (26, 27) . It increases blood pressure, heart rate, and stimulates plasminogen activator inhibitor (PAI) -1 and PAI-2 that result in increasing prothrombotic activities (28) .

Furthermore, it stimulates adrenal gland cortex to secret aldosterone which maintains sodiumpotassium homeostasis by stimulating kidney proximal tubules to increase sodium transportation, resulting in sodium retention and potassium loss (29) . Ang II can also impact the release of prostaglandins, which can influence renal vasoconstriction. Cyclooxygenase (COX) 1-derived prostaglandin E 2 and its receptor have been identified crucial for the Ang II-dependent hypertension (31) . So, Ang II is a critical regulator of blood volume, pressure, and pH. After binding to prorenin/renin receptors, circulating renin and prorenin trigger the local generation of Ang II, and facilitate Ang II-independent signaling cascades (30) .

Ang II can be degraded into Ang III by aminopeptidase-A enzymes on red blood cells . (31) There are other degraded forms of angiotensin II as well, with variable degree of affinity for angiotensin receptors. In fact, the degradation of Ang II with ACE2 enzyme is the basis of treating diabetic nephropathy (32, 33) .

The cardiac RAS is upregulated in the all types of cardiac injuries such as volume overload, myocardial infarction, and heart failure (34-37) as a homeostatic response to restore cardiac function. Compensatory hypertrophy of cardiac myocytes could be induced by Ang II which is an inotropic and growth factor (38) . Ang II is also an essential factor in left ventricular remodeling after myocardial infarction or afterload-induced cardiac hypertrophy (39) .

The zinc metallopeptidase ACE2 is the only known human homologue of ACE. Since its discovery in 2000, ACE2 has been implicated in heart function, hypertension and diabetes, with its effects being mediated, in part, through its ability to convert Ang II to Ang-(1-7) that the latter opposes the pressor, prolifratic, and profibrotic functions of AgII (40, 41) . ACE and ACE2, both are central enzymes in the RAS but ACE2 is not inhibited by ACE inhibitors, it could not convert Ang I to Ang II, as well as, could not inactivate bradykinin (42, 8) . In contrast, ACE2 cleaves a single residue from AngI to generate Ang1-9, and a residue from AngII to generate Ang1-7. So, ACE2 negatively regulates the RAS by inactivating AngII (8) .

ACE2 is a type 1 integral membrane glycoprotein, being expressed and active in most tissues (43, 44) that acts as a carboxypeptidase rather than ACE which acts as dipeptidase. The main locations of ACE2 receptors are cells in contact with the external environment like lung alveolar epithelial cells and enterocytes of the small intestine (11) . ACE2 is also present in arterial and venous endothelial cells, arterial smooth muscle cells, in renal, and cardiovascular tissue (43) (44) (45) . The main substrate of ACE2 appears to be Ang II, but other peptides may also be degraded by ACE2 at lower affinity (44) (45) (46) (47) .

In the kidney, ACE2 and ACE have also antagonistic functions ; while, ACE2 is critical for renal homeostasis and its deficit has been associated with albuminuria and glomerular injury (glomerulosclerosis), ACE is bad for kidney (32, 33, 42) .

In the heart, ACE2 functions as the principal pathway for the metabolism of Ang II (39, 48) , likely through the Nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase system with the p 47 (phox) subunit and consequently diminishes the adverse effects of Ang II in heart (49) . Interestingly, triggered disruption of ACE2 in mice results in severe cardiac contractility defect, increased AngII levels, and upregulation of hypoxia-induced genes in the heart (50), possibly by acting as a natural counterpart of ACE1 (51) , suggesting that the balance of ACE and ACE2 in the heart is an important driving factor for the progressive cardiac disease (52) (53) (54) (55) .

Lung is a major source of Ang II synthesis due to the high level of RAS activity in this organ. In addition, ACE2 is also highly expressed in the lung that appears to have a role in regulating the balance of circulating Ang II/Ang 1-7 levels. Ang II induces pulmonary vasoconstriction in response to hypoxia, which is important in preventing shunting in patients with pneumonia or lung injury (54) . Locally increased Ang II production also triggers increasing vascular permeability facilitating pulmonary edema (55) .

An interesting study by Crackower, et al revealed that there is a Yin-Yang nature of ACE and ACE2 expression (55) . They observed that Ace2 knockout mice show major cardiac contractility defects and increased levels of Ang II. However, double knockouts mice, in which both Ace and Ace2 genes have been deleted, do not show the cardiac defects of the Ace2 knockout alone.

Donoghue, et al examined the effect of transgenically overexpression of ACE2 in mouse heart, and demonstrated that there is a high rate of lethal ventricular arrhythmia, which is associated with the disruption of gap junction formation (56) .

ACE2 has been identified as the functional receptor for SARS-CoV by Li, et al (8) . They showed that ACE2 can be immunoprecipitated by the S1 domain of the SARS-CoV virus and that ACE2 can promote viral replication. The demonstration of ACE2 expression in human organs can potentially identify the possible routes of infection for SARS-CoV, and possible ways of spread and replication throughout the body (11) . Hamming, et al demonstrated that type I and type II pneumocytes are markedly positive for ACE2, while bronchial epithelial cells show only weak staining (11).

Many similarities have been shown between SARS-CoV-2 with the original SARS-CoV using computer modeling (57) . SARS-CoV spike protein has strong binding affinity to human ACE2, based on biochemical interaction studies and crystal structure analysis. SARS-CoV-2 and SARS-CoV spike proteins share 76.5% identity in amino acid sequences and, imperatively, the SARS-CoV-2 and SARS-CoV spike proteins have a high degree of homology (58, 59) .

It was stated that residue 394 (glutamine) in the SARS-CoV-2 receptor-binding domain (RBD), corresponding to residue 479 in SARS-CoV, can be recognized by the critical lysine 31 on the human ACE2 receptor (60, 61) . Further analysis even suggested that SARS-CoV-2 distinguishes human ACE2 more competently than SARS-CoV increasing the ability of SARS-CoV-2 to transmit from person to person (60) . Thus, the SARS-CoV-2 spike protein was also predicted to have a strong binding affinity to human ACE2.

While, upper respiratory tract does not appear to be a primary site of entrance for SARS-CoV due to the modest ACE2 expression (11, 62) that results in low transmissibility of the virus; this is not the case for SARS-CoV2. The potentially higher level of transmissibility of SARS-CoV-2 compared with SARS-CoV, it might be speculated that the new virus might exploit cellular attachmentpromoting factors with higher efficiency than SARS-CoV leads to robust infection of ACE2 + cells in the upper respiratory tract (63) . In addition to lung, extrapulmunary ACE2 positive tissues are vulnerable to SARS-CoV and SARS Cov-2 spread (64, 65, 11) .

Both SARS-CoV and SARS-CoV2 spike glycoprotein (S) use ACE2 as the receptor for entrance into the cytoplasm. The spike (S) protein of coronaviruses facilitates viral entry into target cells. The S1 surface subunit of S protein binds to ACE2 receptor which simplifies viral attachment to the surface of target cells. In addition, the entry requires S protein priming by the type 2 transmembrane cellular proteases (TMPRSS2) which entails S protein cleavage at the S1/S2 and the S2' site and allows fusion of viral and cellular membranes, a process driven by the S2 subunit (63) . The efficiency of ACE2 usage in the process of the SARS-S/ACE2 interface determines the transmissibility of SARS-CoV (59, 66) .

SARS-CoV uses the endosomal cysteine proteases cathepsin B and L (CatB/L) (67), and the serine protease TMPRSS2 (68, 69, 70) for S protein priming in cell lines, so inhibition of both proteases is essential for vigorous blockade of viral entry (71) . However, only TMPRSS2 activity is indispensable for viral spread and pathogenesis in the infected host, while CatB/L activity is unnecessary (70, (72) (73) (74) .

As endosomal low PH is essential for CatB/L activity; Hoffmann and his colleagues employed ammonium chloride to elevate endosomal PH and consequently block the CatB/L activity in order to evaluate the role of CatB/L in the process of SARS-CoV2 entrance into the cells. Ammonium chloride treatment strongly inhibited both SARS-CoV2 and SARS-CoV driven entry into TMPRSS2 − 293T cells, suggesting CatB/L necessity (63) .

As well as, the employment of the serine protease inhibitor camostat mesylate which is active against TMPRSS2 (71) partially, and adding ammonium chloride to camostat mesylate completely blocked the entry of SARS-CoV 2 virus to the TMPRSS2 − 293T cells (63) .

Furthermore, SARS-CoV 2 can use TMPRSS2 for S protein priming and camostat mesylate, an inhibitor of TMPRSS2, blocked SARS-CoV 2 infection of lung cells (63) . They established that antibody responses against SARS-CoV could at least partially protect against SARS-CoV 2 infection (63) .

SARS-CoV2 especially involves alveolar epithelial cells, resulting in respiratory symptoms that are more severe in patients with CVD, which might be linked with increased secretion of ACE2 in these patients compared with healthy individuals. In addition, ACE2 expression could be increased by taking ACE inhibitors medications in hypertensive patients (75) . ACE inhibitors and Angiotensin receptor blockers (ARBs) are widely used in various patients with kidney disease, heart failure, coronary artery disease (CAD), HTN, and diabetes.

The level of ACE2 in the both circulation, and organ including heart and atherosclerotic vessels is increased in patients with coronary artery disease, and heart failure. In addition, a large proportion of the variation in plasma ACE2 levels has been attributed to hereditary factors (76).

Cardiovascular system is at the risk of COVID-19 involvement by the direct infection, as well as due to the indirect involvement by hypoxemia induced by pneumonia and acute respiratory distress syndrome (ARDS).

In a recent case report on 138 hospitalized COVID-19 patients, 16.7% of patients developed arrhythmia and 7.2% experienced acute cardiac injury as well as other COVID-19 associated complications. Some cases of acute onset heart failure, myocardial infarction, myocarditis, and cardiac arrest have also been reported. However, the reporting does not yet define prevalence of cardiac complications in CVD-naïve versus cardiac comorbid patients (77) .

In a retrospective, multicenter cohort Chinese study in which 191 patients were included of whom 137 were discharged and 54 died in hospital. 48% of patients had a comorbidity that hypertension being the most common 30% of patients, followed by diabetes 19% patients, and coronary heart disease 8% patients (78) .

Vascular endothelium is an active organ with paracrine, autocrine, and endocrine functions that is vital for regulation of vascular tone and the maintenance of vascular homoeostasis (79) . Endothelial dysfunction is the primary factor of microvascular dysfunction characterized by vasoconstriction and subsequent organ ischemia, inflammation associated with tissue edema, and pro-coagulant state (80) . The above-mentioned finding is much more important in patients with preexisting endothelial dysfunction including male sex, smoking, hypertension, diabetes, obesity, and established cardiovascular disease, all associated with adverse outcome. (81)

Myocardial injury could complicate the course of COVID-19. According to Chen's report, the first death was a 61-year old man with no previous chronic underlying disease. The patient was admitted in ICU and developed severe respiratory failure, heart failure, and sepsis, and then experienced a sudden cardiac arrest on the 11th day of admission and was declared dead (82) .

In a report released by the National Health Commission of China (NHC), among the people who died from COVID-19, 11.8% of patients without underlying CVD had substantial heart damage, with elevated levels of cardiac troponin I (cTnI) or cardiac arrest during hospitalization (83).

Li, et al conducted a meta-analysis of six studies including 1527 patients with COVID-19 infection to evaluate the prevalence of cardiovascular metabolic diseases in COVID-19 in ICU/severe and non-ICU/ severe patients (84) . They reported 8.0% patients with COVID-19 suffered acute cardiac injury and this incidence was much higher in ICU/severe patients, about 13 folds more than non-ICU/cardiac patients.

In another meta-analysis of four studies suggested that in patients with severe infection, high sensitivity cardiac troponin I (hs-cTn I) was significantly higher at admission compared to those with non-severe course (85) .

Sometimes myocardial involvement could progress rapidly and aggressively, and leads to fulminant myocarditis. One case of fulminant myocarditis has been stated in a 37 years old patient in a case-report by Hu, et al. (6) It has been described that troponin levels remained high in non-survivors throughout the clinical course and increased with illness deterioration (86) . Although, myocardial injury could occur in patients without history of heart failure, it is more common in patients with Pre-existing heart failure. (14.6% vs. 1.5%) (87) .

The most common cause of myocarditis in developed countries is viral infections (169) . Acute Myocardial injury could be the direct result of SARS-CoV2 through ACE2 receptors which is highly expressed in cardiovascular system. (43-45) SARS-CoV viral RNA was detected in 35% of autopsied human heart samples from SARS-CoV infected patients during the Toronto SARS outbreak in Oudit's report (89) . They also endorsed that pulmonary infection with the human SARS-CoV in mice led to an ACE2-dependent myocardial infection (89) .

Another mechanism for cardiac involvement could be cytokines triggered by an imbalanced response by type 1 and type 2 T helper cells (88, 51) . Huang and his colleagues noted that the patients infected with SARS-CoV2 had high amounts of various cytokines like interleukin(IL)1β, Interferon (IFN) γ, interferon γ-induced protein 10 kDa (IP10), and monocyte chemoattractant protein 1(MCP1), probably leading to activated T-helper-1 (Th1) cell responses. Moreover, patients requiring ICU admission had higher concentrations of granulocyte colony stimulating factor (GCSF), IP10, MCP1, macrophage inflammatory protein 1A (MIP1A), and tumor necrosis factorα (TNFα) than did those not requiring ICU admission, suggesting that the cytokine storm was associated with disease severity (90, 91) . However, SARS-CoV2 infection also initiated increased secretion of T-helper-2 (Th2) cytokines (eg, IL4 and IL10) that suppresses inflammation, which differs from SARS-CoV infection (90, 91) .

The third mechanism for cardiac injury is hypoxemia due to respiratory dysfunction caused by COVID-19 (83) . Huang, et al reported that 32% COVID-19 patients had various degree of hypoxaemia and needed high-flow nasal cannula or higher-level oxygen support (90) . Chen, et al reported up to 76% of patients required oxygen therapy (82) . In fact, COVID-19 infection-induced severe pneumonia causes significant gas exchange alteration leading to hypoxaemia that which ominously lessens the energy supply by cell metabolism, therefore increases anaerobic fermentation, causing intracellular acidosis and oxygen free radicals which lead to the phospholipid layer of cell membrane detriment. Meanwhile, hypoxia-induced influx of calcium ions also leads to injury and apoptosis of cardio myocytes (84) .

Acute heart failure could be evolved in patients with COVID-19 with several potential mechanisms. Myocardial injury as mentioned in the previous section could result in acute heart failure (92). Other mechanisms include ARDS-induced hypoxemia, acute kidney injury and subsequent volume overload, exacerbation of chronic heart failure (92), and Sustained/repetitive cardiac arrhythmia (93) .

In a report by Arentz, et al, among 21 patients admitted to an ICU for severe COVID-19, 7 (33.3%) patients developed dilated cardiomyopathy, characterized by globally decreased LV systolic function, clinical signs of cardiogenic shock, elevated creatine kinase (CK), or troponin I levels, or hypoxaemia, without a past history of systolic dysfunction (94) .

Although, to our knowledge, there is no report indicating the incidence of ST elevation myocardial infarction in patients with COVID-19, it could be proposed that the rate of myocardial infarction, acute coronary syndrome, and non-ST-elevation MI will increase among COVID-19 patients particularly among those with underlying cardiovascular disease or risk factors. This conjecture comes from the previous studies reporting the occurrence of ACS and MI among patients with SARS infection (95, 96) .

In a study by Clyton, et al, there was an association between recent respiratory infection and myocardial infarction (97) . In this line, a meta-analysis of case-control studies found a significant association between recent respiratory infection and Acute myocardial infarction (98) .

Some pathophysiological mechanisms can be implicated in this matter. For instance, acute inflammation could result in endothelial dysfunction, consequent vasoconstriction, and ischemia in sensitive organs like heart. Furthermore, inflammation-induced endothelial dysfunction could increase the risk of thrombosis and thrombotic events (80) . In addition, fever, and the surge of inflammation could increase the cardiac demand by increasing metabolism and heat rate, resulting in cardiac ischemia and cardiac events particularly in patients with underlying CVD.

As yet, there is very limited literature available on the occurrence of arrhythmia in the context of COVID-19. In a study of 138 hospitalized patients with COVID-19 in Wuhan, arrhythmia was reported in 16.7% of total patients and in 16 of 36 patients admitted to the ICU (44%), although the authors did not further specify its type (93) . Thereafter, in a subsequent publication from the same institution, ventricular tachycardia (VT)/ventricular fibrillation (VF) was reported as a complication of the COVID-19 disease in 11 of 187 patients (5.9%), with a significantly higher incidence in patients with elevated troponin T (99). However, the largest observational study from China, with 1099 patients from 552 hospitals, did not report any arrhythmia (100).

To our knowledge, there is no specific reports on occurrence of bradycardia in COVID-19 infection. However, an experimental study has shown that coronavirus-infected rabbits have ECG abnormalities including 2nd degree AV block secondary to myocarditis and HF (101). In severely ill patients admitted in ICU due to COVID-19 transient bradycardia and asystole may occur due to patient turning for prone position, intubation, or trachea suction that likely occurs due to the temporary increased vagal tone (102) .

As well as, in patients with underlying CVD on CVD medications, increased QTc interval could be the reason of ventricular arrhythmia due to drug-drug interaction.

Also, a heart rate/temperature discordance as what was observed in typhoid fever was reported in patients with COVID-19 (93, 103) .

There are many reports showing the increased rate of infection with SARS-CoV2 in patients with previous CVD. It appears that the underlying CVD could aggravate the severity of symptoms and the pneumonia due to SARS-CoV2 (83) . In one study, among the patients with severe symptoms of COVID-19, 25% had heart disease and 44% had arrhythmia (77) . Among the comorbid conditions, cardiac disease and diabetes increased the risk of death by twice as much as other risk factors (104) .

According to mortality data released by NHC, 17% of patients had a history of coronary heart disease. Furthermore, data showed that patients aged >60 years who were infected with SARS-CoV2 had more systemic symptoms and more severe pneumonia than patients aged ≤60 years (83) .

As stated by Li, et al in a meta-analysis respecting the prevalence and impact of cardio-metabolic comorbidities on COVID-19, the proportion of cardio-cerebrovascular disease was statistically significant higher in ICU/severe patients compared to the non-ICU/severe cases [RR = 3.30, 95% CI (2.03, 5.36), Z = 4.81, P < 0.00001] (84).

It is expected that patients with acute coronary syndrome (ACS) and acute myocardial infarction(AMI) to be at higher risk of mortality due to COVID-19 infection. This is truly supported by the fact that the patients with severe infection are susceptible to increased ischemia and cardiac demand, and consequently result in poorer prognosis (83) . Correspondingly, in patients with an underlying cardiac insufficiency, infection with SARS-CoV2 could deteriorate the condition and lead to death (83) .

Cardiac troponins are known to have a crucial role in the evaluation of patients with acute chest pain (76) . In a recent meta-analysis by Lippi, et al, it was shown that cardiac troponin I (cTnI) values are significantly increased in patients with severe SARS-CoV2 infection compared to those with milder forms of disease (85) . Therefore, it seems judicious to measure cardiac damage biomarkers instantly after hospitalization for SARS-CoV2 infection, and subsequent monitoring during hospital stay that might help identifying a subset of patients with possible cardiac injury, and predicting the progression of COVID-19 towards a worse clinical picture.

HTN is a comorbid condition which has been reported to be associated with increased mortality in patients with COVID-19 infection. Chen and his colleagues reported that 113(14.4%) patients who died from COVID-19 compared with those of 161 patients who recovered, more likely had HTN and diabetes (85) . Furthermore, according to the China Center for Disease Control and Prevention's report of 44 000 people with laboratory confirmed covid-19, HTN and diabetes were among comorbid conditions with higher risk of mortality. (4) In addition, a meta-analysis of eight studies including 46248 patients with laboratory confirmed COVID-19 showed that the subjects with more severe disease more likely had HTN (odds ratio 2.36 (95%confidence interval 1.46 to 3.83) (105) .

In this track, Li, et al described that HTN was the most prevalent cardiovascular metabolic comorbidity (17.1%, 95% CI 9.9-24.4%) followed by cardio-cerebrovascular disease (16.4%, 95% CI 6.6-26.1%), and diabetes (9.7%, 95% CI 6.9-12.5%). Although, the overall proportion of HTN, cardia-cerebrovascular diseases and diabetes were about twofolds, threefolds and twofolds in ICU/severe cases compared with their non-ICU/severe counterparts respectively, they did not find that people with HTN and diabetes were more susceptible to COVID-19 infection (84) .

Possible mechanisms of the adverse effect of HTN on the process of COVID-19 infection might be in part due to the increased expression of ACE2 receptors in hypertensive patients taking reninangiotensin-aldosterone (RAS) inhibitors based on some animal and human studies (106, 107) . Also, hypertensive patients might have underlying cardiovascular atherosclerotic disease, diastolic dysfunction, and chronic kidney disease which all expose them at higher risk of morbidity and mortality.

Older age which is a cardiovascular risk and the main cause of death among elderly population (168) was associated with higher risk of severe COVID-19 in national surveys database in the US, China, and Italy (108) . The case fatality rate in those three databases exceeded 1% around age of 50-55 years and 10% above 80-85 years (above 70 years in Italy). Those studies reporting the results both based on unadjusted and multivariable models described the unchanged pattern of the effect size of age after adjustment for comorbidities (109, 86) .

In the US, among individuals older than 60 years ranges from 17 to 27%, the percentage of hospitalized patients requiring care in an ICU is 27-71% with an infection fatality rate (IFR) ranging from 2.2 to 9.3% (110) .

According to the extensive evidence, Smoking has been accepted as a negative risk factor on lung health and its causal association with overabundance of respiratory diseases likely due to the detrimental effect on immune system (111, 112) .

Previous studies showed that smoking status was associated with higher mortality in the previous MERS-CoV outbreak (113, 114) . Among the observational studies concerning the clinical characteristics of patients with COVID-19, a large study consisting of 1099 patients conducted by Guan et al from multiple regions of mainland China (101) . Descriptive results on the smoking status of patients revealed that 173 out of 1099 patients with COVID-19 had severe symptoms, and 926 had non-severe symptoms. Among the patients with severe symptoms, 16.9% were current smokers and 5.2% were former smokers, in contrast to patients with non-severe symptoms where 11.8% were current smokers and 1.3% were former smokers. Moreover, in the group of patients that either needed mechanical ventilation, admission to ICU or died, 25.5% were current smokers and 7.6% were former smokers. In contrast, in the group of patients that did not have these adverse outcomes, only 11.8% were current smokers and 1.6% were former smokers.

A systematic review and meta-analysis including 5 studies identified the association between smoking and severity of symptoms as smokers had 1.4 times more likely (RR=1.4, 95% CI: 0.98-2.00) to have severe symptoms of COVID-19 and approximately 2.4 times more likely to be admitted to ICU, need mechanical ventilation or die compared to non-smokers (RR=2.4, 95% CI: 1.43-4.04). However, the results of this meta-analysis have not been adjusted for other factors which might assist the disease progression (115) .

Diabetes is a well-known risk factor for CVD accompanied by obesity, HTN, and CVD in many cases, which is associated with increased rate of mortality in patients with COVID-19. Evidence of the higher risk of mortality among persons with diabetes and the two previous SARS corona viruses (SARS, and MERS) has been reported (116) (117) (118) .

Bearing in mind the high prevalence of cardiovascular disease (CVD), obesity, and hypertension in patients with DM, it is still unknown whether DM independently contributes to this increased risk. However, according to one study, plasma glucose levels and DM are independent predictors for mortality and morbidity in patients with SARS (5) In diabetes, there has been an enhanced ACE2 expression in different organs like lung, kidney, heart, and pancreas in rodent and in the lung of human models (119) (120) (121) , which might result in facilitating the virus entry to the cell. In addition, circulating levels of furin, a cellular protease involved in facilitating viral entry by cleaving the S1 and S2 domain of the spike protein of the virus, are elevated in patients with DM (122) . Interestingly, Chen, et al revealed that in patients with DM and HTN, the clearance of SARS-CoV2 was delayed, a finding that needs to be confirmed in larger studies (123) .

Potential mechanisms that may increase the susceptibility for COVID-19 in patients with DM include higher affinity for cellular binding and efficient virus entry, decreased viral clearance, diminished T cell function, increased susceptibility to hyper inflammation and cytokine storm syndrome, and comorbid conditions like CVD (124) .

Obesity and severe obesity are well established as risk factors for hospitalization and mechanical ventilation. The increased risk of hospitalization and mechanical ventilation in these patients is not surprising because obesity is connected with decreased respiratory reserve volume, functional capacity, and respiratory system compliance. In addition, abdominal obesity comprises pulmonary function further in supine position due the decreased diaphragmatic excursion, making ventilation more difficult. Furthermore, increased inflammatory cytokines associated with obesity may contribute to the increased morbidity associated with obesity in COVID-19 infections (125).

Zheng, et al reported that the presence of obesity in metabolic associated fatty liver disease (MAFLD) patients was associated with a significant increased risk of severe COVID-19 illness even after adjusting for other risk factors (126) .

A French retrospective cohort study in patients with COVID-19 illness admitted in ICU, identified the significant increased need for invasive mechanical ventilation (IMV) with higher grade of obesity. Overall, 68.6% required IMV of whom the greatest proportion of patients needed IMV was the patients with BMI >35 kg/m2 (85.7%). BMI had an independent risk factor for severity of the disease and need for IMV (127) .

According to the report of National Center for Health Statistics, the prevalence of adult obesity and severe obesity in 2017 to 2018 has increased in the US since 2009 to 2010 and is now 42% and 9%, respectively (128) . Concerning this report, as well as based on the above-mentioned studies and the compatible results of the previous studies about other respiratory infection like H1N1 and their increased mortality and morbidity with increased BMI, it must serve as a caution for the care of patients with obesity and particularly patients with severe obesity. These observations also emphasize the need for increased observance, precedence on detection and testing, and forceful therapy for patients with obesity and COVID-19 infections (125) .

In addition to above-mentioned mechanisms, other various mechanisms concerning the increased risk of mortality and morbidity in COVID-19 patients with traditional risk factors are mentioned in the table 1. 

Underlying coronary artery disease (161) Decreased respiratory compliance (167) Decreased functional capacity (167) Underlying HTN (167) Impaired immunity (111, 112) Old age

Underlying cardiovascular disease (161) Impaired immunity (166)

Decrease respiratory reserve (125) Decreased functional capacity (125) Underlying diabetes (165) Underlying coronary artery disease (161) Underlying HTN (165) Increased inflammatory cytokines(125)

COVID-19 infection may also be connected with an elevated long-term CV risk. Previous studies in patients with pneumonia has established the long period hypercoagulability state and systemic inflammatory activity. (130) Besides, follow-up studies of the SARS epidemic demonstrated that patients with a history of SARS-coronavirus infection often had hyperlipidemia, CV system abnormalities or glucose metabolism disorder. However, the explanation for metabolic disorder in survivors of SARS could be due to the use of pulses of methylprednisolone not because of the infection itself (130) . Although, there is no long-term effects of SARS-CoV2 infection, it is needed to take more inspection for recovered patients in the future based on the information available from SARS.

Although, currently there is no proven therapeutic medication or vaccine for SARS-CoV2, and the present best strategy to treat patients with SARS-CoV2 infection is supportive approach, there are some potential medications under investigation. Some of these medications might have cardiovascular adverse effects that must be closely observed.

Whether, ARBs like losartan and olmesartan which are therapeutic medications widely used in hypertensive, diabetes and kidney disease patients, aggravate the SARS-CoV2 infection by increasing the expression of ACE2 as the functional receptor of the virus or prevent infected patients to progress toward ARDS has remained to be established.

Circulating levels of ACE2 are increased not only in patients with HTN (160) or diabetes (131, 132) , but also further elevated in patients using these medications (131, 132) . Utilizing these medications could increase the expression of cardiac ACE2 expression about three-fold following chronic treatment (28 days) after myocardial infarction induced by coronary artery ligation of rats (75) . Losartan was also shown to upregulate renal ACE2 expression in chronically treated rats (133) .

A recent hypothesis suggested that ARBs might be beneficial for patients infected by COVID-19 who experience pneumonia (134) . At the first glance, it appears that the high expression of ACE2 by ARBs aggravates SARS-CoV2 infection; conversely, it might keep the patients against acute lung injury which is one of the main causes of death due to the virus infection. The latter hypothesis comes from the fact that infection with SARS-CoV2 downregulates the ACE2 receptors and consequently increases the level of AngII which has vasoconstrictive functions and could worsen the lung involvement. While, taking ARBs diminishes the production of angiotensin caused by viral COVID-19-mediated downregulation of ACE2. As well as, upregulating ACE2 might be another potential mechanism that helps reduce angiotensin production by ACE and increasing the production of the vasodilator angiotensin 1-7 (135) .

In this matter, multiple cardiac societies, including ACC, AHA, and ESC currently recommend in patients with COVID-19 to not start ACE inhibitors or ARBs but to continue prior either class of ACE inhibitors or ARBs (136).

A widely used antimalarial and autoimmune disease drug named Chloroquine has been reported as a potential broad-spectrum antiviral drug through blocking virus infection by increasing endosomal PH required for virus/cell fusion, as well as by glycosylation of cellular receptors of SARS-CoV (137) (138) (139) . Chloroquine has been reported to be possibly effective in blocking SARS-CoV-2 infection at both entry and post-entry stages in vitro (140) . In addition, Chloroquine acts as an immunomodulatory drug which could synergistically enhance its antiviral effect in vivo (105) .

However, chloroquine has been shown to cause AV blocks and prolonged QT interval-corrected (QTc). Also, hydroxychloroquine, which is the more potent synthetic form of chloroquine, is being used for empirical management of COVID-19 based on a small French trial along with azithromycin, a macrolide antibiotic (141, 142) . Hydroxychloroquine can similarly produce conduction defects in the heart. Additive effects of concomitant use of beta-blockers or calcium channel blockers can induce severe bradycardia leading to cerebral hypoperfusion with syncope and or fall (143) .

The combination of azithromycin and chloroquine products has been utilized with improved recovery of symptoms (141, 142) . Since, azithromycin is known to increase QTc, it could theoretically further increase QTc in combination with chloroquine and increase the risk of torsade de point and ventricular arrhythmia. Monitoring of QTc along with electrolytes (particularly potassium) is necessary when these medications are going to be started by physicians (144) .

Lopinavir/ritonavir are FDA-approved drugs for HIV-1 infection (145) . A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19 by Cao B, et al has been shown no survival benefit following treatment with lopinavir/ritonavir in hospitalized adult patients with severe COVID-19. At this time, this is not currently a recommended treatment option for COVID patients. However, as there is not a definite treatment for COVID-19 infection, these drugs might be used in severe ill patients in some centers. Therefore, it must be noticed that these medications could prolong PR and QT intervals leading to high-grade AV blocks and rarely torsade de Pointes. As well as, they could increase serum lipid levels, and decrease the serum concentration of clopidogrel and prasugrel, while increase the serum level of ticagrelor and statins.

In addition, lopinavir/ritonavir enhances the effects of factor Xa inhibitors such as apixaban and rivaroxaban through the inhibition of CYP3A4, thereby increasing bleeding risk. Thus, extreme attention is warranted in patients on multiple cardiovascular medications (145) .

Ribavirin which is sometimes combined with lopinavir/ritonavir, has not been established to directly affect the heart but can indirectly influence on heart by increasing by the levels of lopinavir/ritonavir. It has also been reported to reduce the effect of warfarin and to have noncardiac side effects (146) .

Remdesivir is an adenosine analogue, which incorporates into nascent viral RNA chains and results in pre-mature termination (147) , that has been recognized as a promising antiviral drug against a wide range of RNA viruses including SARS CoV infection in cultured cells, mice and nonhuman primate (NHP) models (147) .

Wang, et al demonstrated that remdesivir functioned at the stage of post virus entry, and revealed its high efficacy in the control of SARS-CoV2 infection in vitro (147) .

Although, its side effects have not yet been well known, there was a patient who developed hypotension and bradycardia when this medication was used to treat Ebola (148) .

Colchicine which is an alkaloid extracted from plants of the genus Colchicum (autumn crocus) has a well-established therapeutic usage in gout and familial Mediterranean fever (FMF) (149) . However, it has also been used in other diseases including Behcet's disease, pericarditis, CAD, and other inflammatory and fibrotic conditions. Current results suggest that colchicine downregulates multiple inflammatory pathways and modulates innate immunity (149) .

Colchicine has been utilized safely in a variety of cardiovascular clinical conditions including acute pericarditis (155) , prevention of post-pericardiotomy syndrome (150), prevention of atrial fibrillation recurrence after cardiac surgery or ablation procedures (151) .

Colchicine is a non-selective inhibitor of NLRP3 inflammasome (152) . In the experimental models, it has been found that inflammasome NLRP3 is a major pathophysiological component in the development of ARDS (153, 154) . On the other hand, SARS-CoV2 proteins such as viroporins E, 3a and 8A play a considerable role in viral replication and pathogenetic sequelae (155) . There are evidence supporting that these 3 SARS-CoV2 proteins provoke the activation of inflammasome NLP3 (156, 157) . Based on the said information, it is assumed that colchicine might be an impending useful and safe drug to limit the myocardial necrosis and pneumonia in the context of COVID-19. A clinical trial based on this hypothesis is undergoing.

COVID-19 tends to be more severe in patients with CVD, HTN, and diabetes. The cardiac troponin I measurement and its monitoring as an easy, and available laboratory test could be considered in high risk hospitalized patients with COVID-19. On the other hand, in patients with underlying CVD, and traditional risk factors, it is sensible to screen these patients for SARS-CoV2 in order to plan an integrate, aggressive therapeutic strategies.

To note, there are currently more than 80 clinical trials to test a variety of potential SARS-CoV-2 treatments (158) . Since both SARS-CoV and SARS-CoV2 share ACE2 receptors to entry to the cells, it is wise to utilize the results of the previous researches of SARS-CoV to SARS-CoV2. Among the potential drugs, remdesivir and chloroquine are the two most focused drugs. Now, six clinical trials regarding remdesivir are undergoing performance (159) .

Some potential used drugs have adverse cardiovascular side effects that must be noted by the physicians. Until finding a proper, approved medication, the conservative approach, and focus on the adverse effects of potential, and empirically-used drugs must be the priority.

World Health Organization. Coronavirus disease 2019 (COVID-19) situation report-51

The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS

Cardiovascular complications of severe acute respiratory syndrome

Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Mice transgenic from human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

History and recent advances in coronavirus discovery

Coronaviruses: an overview of their replication and pathogenesis

Origin and evolution of pathogenic coronaviruses

Middle East Respiratory Syndrome Coronavirus (MERS-CoV): a perpetual challenge

ECDC Risk assessment guidelines for infectious diseases transmitted on aircraft (RAGIDA)

Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia

Close relative of human Middle East respiratory syndrome coronavirus in bat

A novel coronavirus from patients with pneumonia in China

Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event

The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition

Physiology, hemodynamics, endothelial function, renin-angiotensin-aldosterone system, sympathetic nervous system

Purification and characterization of recombinant human renin for X-ray crystallization studies

The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vasc. Health Risk Manag

Angiotensin I-converting enzyme: genotype and disease associations

Angiotensin-converting enzyme overexpression in myelocytes enhances the immune response

Angiotensin-converting enzyme and its clinical significance--a review

Angiotensin II induces plasminogen activator inhibitor-1 and −2 expression in vascular endothelial and smooth muscle cells

Proximal sodium reabsorption: an independent determinant of blood pressure response to salt Hypertens

Vascular Biology of the Placenta

Conversion of renal angiotensin II to angiotensin III is critical for AT2 receptor-mediated natriuresis in rats

Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy

ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury

Expression of renin-angiotensin system components in the heart, kidneys, and lungs of rats with experimental heart failure

The renin-angiotensin system and volume overloadinduced changes in cardiac collagen and elastin

Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure

Expression of angiotensin-converting enzyme in remaining viable myocytes of human ventricles after myocardial infarction

Autocrine release of angiotensin II mediates stretchinduced hypertrophy of cardiac myocytes in vitro

Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart

Counterregulatory actions of angiotensin-(1-7). Hypertension

ACE2: from vasopeptidase to SARS virus receptor

Role of ACE2 in diastolic and systolic heart failure

A human homolog of angiotensin-converting enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme

The angiotensin-converting enzyme gene family: genomics and pharmacology

Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism

The angiotensin converting enzyme 2/Ang

Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47phox NADPH oxidase subunit

Angiotensin-converting enzyme 2 is an essential regulator of heart function

Hypothesis: ACE2 modulates blood pressure in the mammalian organism

Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II

Candesartan ameliorates cardiac dysfunction observed in angiotensin-converting enzyme 2-deficient mice

Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale

Angiotensin-converting enzyme 2 protects from severe acute lung failure

Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its Spike protein for risk of human transmission

Structure of SARS coronavirus Spike receptor-binding domain complexed with receptor

Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS

Mechanisms of host receptor adaptation by severe acute respiratory syndrome coronavirus

Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts

SARS-CoV-2 Cell Entry Depends on ACE2

Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways

Multiple organ infection and the pathogenesis of SARS

Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2

Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry

Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response

Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2

TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection

Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry

A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry

Clinical Isolates of Human Coronavirus 229E Bypass the Endosome for Cell Entry

Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry

Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors

High-sensitivity cardiac troponins: sex-specific values in clinical practice. Precision or confusion?

Clinical Characteristics of 138 Hospitalized Patients with2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

The assessment of endothelial function: from research into clinical practice

Endothelial dysfunction -a marker of atherosclerotic risk

Endothelial cell infection and endotheliitis in COVID-19

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

COVID-19 and the cardiovascular system

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

The clinical pathology of severe acute respiratory syndrome (SARS): a report from China

SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

ESC guidance for the diagnosis and management of CV disease during the COVID-19 pandemic

Clinical Characteristics of 138 Hospitalized Patients With

Novel Coronavirus-Infected Pneumonia in Wuhan, China

Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis

Recent respiratory infection and the risk of myocardial infarction

Acute myocardial infarction and influenza: a metaanalysis of case-control studies

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

Clinical characteristics of coronavirus disease 2019 in China

ECG changes after rabbit coronavirus infection

European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS)

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine

Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS)

Prevalence of comorbidities in the novel Wuhan coronavirus(COVID-19) infection: a systematic review and meta-analysis

Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension

Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Clinical progression of patients with COVID-19 in Shanghai

Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand

Secular trends in smoking in relation to prevalent and incident smoking-related disease: A prospective population-based study

Are healthy smokers really healthy?

MERS transmission and risk factors: a systematic review

Cigarette smoking and infection

COVID-19 and smoking: A systematic review of the evidence

Hospitalization for ambulatory-care-sensitive conditions in Taiwan following the SARS outbreak: a population-based interrupted time series study

Clinical outcomes of current medical approaches for Middle East respiratory syndrome: a systematic review and meta-analysis

Characterization of ACE and ACE2 Expression within Different Organs of the NOD Mouse

ACE and ACE2 activity in diabetic mice

Exploring diseases/traits and blood proteins causally related to expression of ACE2, the putative receptor of 2019-nCov: A Mendelian randomization analysis (Preprint). medRxiv

Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality

Hypertension and diabetes delay the viral clearance in COVID-19 patients (Preprint). medRxiv

COVID-19 pandemic, coronaviruses, and diabetes mellitus

Obesity and its Implications for COVID-19 Mortality

Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease

Obesity: the "Achilles heel" for COVID-19

Prevalence of obesity and severe obesity among adults: United States

The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases

Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine

Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease

Serum concentration of renin-angiotensin system components in association with ACE I/D polymorphism among hypertensive subjects in response to ACE inhibitor therapy

Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats

Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia

Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics

Patients taking ACE-I and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician

New insights into the antiviral effects of chloroquine

Antiviral Activity of Chloroquine against Human Coronavirus OC43 Infection in Newborn Mice

Esterase inhibitors prevent lysosomal enzyme redistribution in two noninvasive models of experimental pancreatitis

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the

Cardiac Manifestations Of Coronavirus (COVID-19)

Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset

Inhibition of warfarin activity by ribavirin

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Controlled Trial of Ebola Virus Disease Therapeutics

Colchicine--Update on mechanisms of action and therapeutic uses

ESC Guidelines on the diagnosis and management of pericardial diseases

HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary

The NLRP3 inflammasome in acute myocardial infarction

Critical Role for the NLRP3 Inflammasome during Acute Lung Injury

Regulation of the NLRP3 inflammasome and macrophage pyroptosis by the p38 MAPK signaling pathway in a mouse model of acute lung injury

Role of Severe Acute Respiratory Syndrome Coronavirus Viroporins E, 3a, and 8a in Replication and Pathogenesis

Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC

Severe Acute Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3 Inflammasome

More than 80 clinical trials launch to test coronavirus treatments

Aldosterone System (RAAS) IV: Circulating ACE2 as a Biomarker of Systolic Dysfunction in Human Hypertension and Heart Failure

Risk Factors for Coronary Artery Disease: Historical Perspectives

Immune dysfunction in patients with diabetes mellitus (DM)

Diabetes mellitus and hypertension: key risk factors for kidney disease

Diastolic dysfunction: a link between hypertension and heart failure

The medical risks of obesity

Aging and immune function: molecular mechanisms to interventions

Clinical Effects of Cigarette Smoking: Epidemiologic Impact and Review of Pharmacotherapy Options

Population ageing and cardiovascular health: the case of Greece

Recurrent viral myocarditis: The emerging link toward dilated cardiomyopathy

There is not any acknowledgment to declare

Funding: There is no funding support to declare